Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?-Reference-Cited by-同舟云学术

Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?

Published:2006-09 Issue:7 Volume:1 Page:684-691
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kurata Takayasu,Matsuo Keitaro,Takada Minoru,Kawahara Masaaki,Tsuji Masahiro,Matsubara Yuka,Otani Nagahiro,Matsuyama Shigeki,Muraishi Kenya,Fujita Tetsuya,Ishikawa Masato,Koyano Keita,Okamoto Isamu,Satoh Taroh,Tamura Kenji,Nakagawa Kazuhiko,Fukuoka Masahiro

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference65 articles.

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials;Non-Small Cell Lung Cancer Collaborative Group;BMJ,1995

2. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The Tax 326 Study Group;Fossella;J Clin Oncol,2003

3. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial;Kelly;J Clin Oncol,2001

4. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

5. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000